ISAM-140

ISAM-140

Names
IUPAC names (±)-Isopropyl 4-(Furan-2-yl)-2-methyl-1,4-dihydrobenzo-[4,5]imidazo[1,2-a]pyrimidine-3-carboxylate, 4-(2-Furanyl)-4,10-dihydro-2-methyl-pyrimido[1,2-a]benzimidazole-3-carboxylic acid 1-methylethyl ester
Other names ISAM140
Identifiers
CAS Number	932191-62-3  Y
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL3787197
ChemSpider	12904393  N
IUPHAR/BPS	11223
PubChem CID	17198004
InChI InChI=1S/C19H19N3O3/c1-11(2)25-18(23)16-12(3)20-19-21-13-7-4-5-8-14(13)22(19)17(16)15-9-6-10-24-15/h4-11,17H,1-3H3,(H,20,21) Key: NYHLRBMDXQBOIB-UHFFFAOYSA-N
SMILES CC1=C(C(N2C3=CC=CC=C3N=C2N1)C4=CC=CO4)C(=O)OC(C)C
Properties
Chemical formula	C19H19N3O3
Molar mass	337.37
Appearance	White solid
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N  verify  (what is  YN ?) Infobox references

ISAM-140 is a selective non-xanthinic adenosine A_2B receptor antagonist. Discovered in 2016, ^[1] it has a K_i of 3.49 nM on the A_2B receptor and >1000-fold selectivity with respect to the other three adenosine receptor subtypes. It has been shown to help the immune system to attack cancer cells in in vitro assays by rescuing T and NK cell proliferation, cytokine release, and TIL infiltration. ^[2]

References

1. El Maatougui, Abdelaziz; Azuaje, Jhonny; González-Gómez, Manuel; Miguez, Gabriel; Crespo, Abel; Carbajales, Carlos; Escalante, Luz; García-Mera, Xerardo; Gutiérrez-de-Terán, Hugo; Sotelo, Eddy (2016-03-10). "Discovery of Potent and Highly Selective A 2B Adenosine Receptor Antagonist Chemotypes" . Journal of Medicinal Chemistry. 59 (5): 1967–1983. doi:10.1021/acs.jmedchem.5b01586. ISSN   0022-2623. PMID   26824742.
2. Tay, Apple Hui Min; Prieto-Díaz, Rubén; Neo, Shiyong; Tong, Le; Chen, Xinsong; Carannante, Valentina; Önfelt, Björn; Hartman, Johan; Haglund, Felix; Majellaro, Maria; Azuaje, Jhonny (2022-05-01). "A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models". Journal for ImmunoTherapy of Cancer. 10 (5) e004592. doi: 10.1136/jitc-2022-004592 . ISSN   2051-1426. PMC   9115112 . PMID   35580926.